Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Shift in AP-2alpha localization characterizes astrocytoma progression.

Ramona Britto1, S Umesh, A S Hegde

  • 1Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.

Cancer Biology & Therapy
|May 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repurposing salmon calcitonin for glioblastoma treatment: Targeting Yes-associated Protein (YAP)/ Transcriptional co‑activator with PDZ‑binding motif (TAZ) via hippo pathway activation.

Neuro-oncology advances·2026
Same author

AOSNP-ADAPTR resource level-based recommendations on practical diagnostic strategies for ependymomas.

Brain pathology (Zurich, Switzerland)·2026
Same author

Utility of Immunohistochemistry in Subtyping Posterior Fossa Group A Ependymoma: A Retrospective Study.

Asian journal of neurosurgery·2025
Same author

Desmoplastic Myxoid Tumor of the Pineal Region, <i>SMARCB1</i>-Mutant: Report of 2 Examples of an Extremely Rare Entity.

International journal of surgical pathology·2025
Same author

AOSNP-ADAPTR resource level-based recommendations on practical diagnostic strategies for WHO CNS5 adult-type diffuse gliomas.

Brain pathology (Zurich, Switzerland)·2025
Same author

cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.

Brain pathology (Zurich, Switzerland)·2025

Activator protein 2alpha (AP-2alpha) expression shifts from the nucleus to the cytoplasm in higher-grade astrocytomas, indicating increased malignancy. Decreased nuclear AP-2alpha correlates with better prognosis in glioblastoma multiforme.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Activator protein 2alpha (AP-2alpha) is frequently lost in advanced cancers, including gliomas.
  • Understanding AP-2alpha expression patterns is crucial for astrocytoma progression insights.

Purpose of the Study:

  • To analyze AP-2alpha expression in astrocytomas across different grades at RNA and protein levels.
  • To investigate the correlation between AP-2alpha expression, localization, and patient outcomes.

Main Methods:

  • Real-time quantitative PCR (qPCR) for RNA expression analysis.
  • Immunohistochemistry for protein expression and localization assessment.
  • Analysis of astrocytoma samples from Grade I to IV and normal brain controls.

Related Experiment Videos

Main Results:

  • No clear RNA expression pattern with tumor grade was observed.
  • Nuclear AP-2alpha expression did not show a complete loss in higher grades.
  • Cytoplasmic AP-2alpha expression increased significantly in higher-grade astrocytomas (Grade III and IV), while nuclear expression decreased.
  • Decreased nuclear AP-2alpha expression in glioblastoma multiforme indicated a better prognosis.

Conclusions:

  • The shift of AP-2alpha from the nucleus to the cytoplasm correlates with increased astrocytoma malignancy.
  • AP-2alpha localization, not just expression level, plays a critical role in astrocytoma progression.
  • Altered AP-2alpha localization may serve as a biomarker for astrocytoma malignancy and patient prognosis.